214 related articles for article (PubMed ID: 22127954)
1. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract][Full Text] [Related]
2. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
3. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Dong Z; Meller J; Succop P; Wang J; Wikenheiser-Brokamp K; Starnes S; Lu S
Int J Oncol; 2014 Sep; 45(3):978-84. PubMed ID: 24913497
[TBL] [Abstract][Full Text] [Related]
4. Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.
Kupert E; Anderson M; Liu Y; Succop P; Levin L; Wang J; Wikenheiser-brokamp K; Chen P; Pinney SM; Macdonald T; Dong Z; Starnes S; Lu S
BMC Cancer; 2011 Dec; 11():513. PubMed ID: 22151235
[TBL] [Abstract][Full Text] [Related]
5. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Dong Z; Liu Y; Levin L; Oleksowicz L; Wang J; Lu S
Oncol Rep; 2011 Jun; 25(6):1511-6. PubMed ID: 21455584
[TBL] [Abstract][Full Text] [Related]
6. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Halpern AL; Kohtz PD; White AM; Houk AK; Rehring JF; Hanson L; McCarter MD; Joshi M; Meng X; Fullerton DA; Weyant MJ
Dig Dis Sci; 2021 Mar; 66(3):784-795. PubMed ID: 32277371
[TBL] [Abstract][Full Text] [Related]
7. CD64 and Group II Secretory Phospholipase A2 (sPLA2-IIA) as Biomarkers for Distinguishing Adult Sepsis and Bacterial Infections in the Emergency Department.
Tan TL; Ahmad NS; Nasuruddin DN; Ithnin A; Tajul Arifin K; Zaini IZ; Wan Ngah WZ
PLoS One; 2016; 11(3):e0152065. PubMed ID: 27003588
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Yu JA; Mauchley D; Li H; Meng X; Nemenoff RA; Fullerton DA; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1185-91. PubMed ID: 23079010
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Lu S; Dong Z
Int J Oncol; 2017 Jun; 50(6):2113-2122. PubMed ID: 28440478
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.
Menschikowski M; Hagelgans A; Schuler U; Froeschke S; Rosner A; Siegert G
Pathol Oncol Res; 2013 Oct; 19(4):839-46. PubMed ID: 23722320
[TBL] [Abstract][Full Text] [Related]
11. Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
Xin H; Chen ZY; Lv XB; Liu S; Lian ZX; Cai SL
Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):999-1004. PubMed ID: 23661511
[TBL] [Abstract][Full Text] [Related]
12. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
[TBL] [Abstract][Full Text] [Related]
13. AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.
El Hadri K; Denoyelle C; Ravaux L; Viollet B; Foretz M; Friguet B; Rouis M; Raymondjean M
PLoS One; 2015; 10(7):e0132498. PubMed ID: 26162096
[TBL] [Abstract][Full Text] [Related]
14. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
15. Secretory phospholipase A
Chovatiya GL; Sarate RM; Sunkara RR; Gawas NP; Kala V; Waghmare SK
Sci Rep; 2017 Sep; 7(1):11619. PubMed ID: 28912581
[TBL] [Abstract][Full Text] [Related]
16. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.
Jiang J; Neubauer BL; Graff JR; Chedid M; Thomas JE; Roehm NW; Zhang S; Eckert GJ; Koch MO; Eble JN; Cheng L
Am J Pathol; 2002 Feb; 160(2):667-71. PubMed ID: 11839587
[TBL] [Abstract][Full Text] [Related]
17. Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Wang M; Hao FY; Wang JG; Xiao W
Eur Rev Med Pharmacol Sci; 2014; 18(18):2648-54. PubMed ID: 25317799
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Luchtefeld M; Bandlow N; Tietge UJ; Grote K; Pfeilschifter J; Kaszkin M; Beck S; Drexler H; Schieffer B
Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
[TBL] [Abstract][Full Text] [Related]
19. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue.
Tribler L; Jensen LT; Jørgensen K; Brünner N; Gelb MH; Nielsen HJ; Jensen SS
Anticancer Res; 2007; 27(5A):3179-85. PubMed ID: 17970059
[TBL] [Abstract][Full Text] [Related]
20. Modulation of lipid profile by secretory phospholipase A2 group IIA: Verification with a transgenic mouse model.
Liang L; Song J; Miao S; Xie Q; Li W; Huang H; Shen D; Zhang W
Biochem Biophys Res Commun; 2024 Jun; 712-713():149955. PubMed ID: 38640737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
